Last updated: 2026-09-16 09:45:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Lexeo Therapeutics, Inc. (LXEO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $4,13, with a market capitalisation of $345,41M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,99 to $10,99. This page covers its latest market performance, valuation, price trends and company information.
$345,41M | |
$4,13 | |
$22,33 | |
$1,45 | |
$4,13 | |
1,00 | |
916,63K | |
-- | |
$10,99 | |
$3,99 | |
-- | |
-- |
Lexeo Therapeutics, Inc. (LXEO) is trading at $4,13 in pre-market trading as of 2026-09-16 08:01:00, unchanged from the previous close of $4,13
Pre-market trading shows how investors are pricing LXEO before the regular session opens. The current pre-market price is near the previous close, indicating neutral early trading sentiment.
Over the past seven days, Lexeo Therapeutics, Inc. (LXEO) moved from $4,89 to $4,13, representing a decline of 15,54% ($0,76).
The stock traded between $4,01 and $4,99 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 718,52 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2,0%
LXEO is currently trading at $4,13, placing it 2,0% of the way from its 52-week low of $3,99 to its 52-week high of $10,99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 59 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lexeo Therapeutics, Inc. (LXEO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.